📊 ENLV Key Takeaways
Is Enlivex Ltd. (ENLV) a Good Investment?
Enlivex Ltd. presents insufficient financial data for meaningful fundamental analysis, with no revenue, profitability metrics, or recent insider activity disclosed. The lack of available metrics severely limits the ability to assess financial health, operational efficiency, or growth quality, indicating either pre-revenue status or significant reporting gaps.
Enlivex's reported 2025 profitability is not supported by operating fundamentals: revenue remained zero, operating loss was $15.0 million, and net income of $1.24 billion came primarily from unrealized gains on digital assets and a related option rather than from its clinical-stage business. Financial health improved sharply on paper, with $1.93 billion of equity and management stating cash resources are sufficient through the end of 2027, but asset quality is highly speculative because roughly 99.5% of total assets were tied to RAIN-related holdings at year-end. The core business remains pre-revenue, cash-burning, and dependent on clinical progress plus future financing.
Why Buy Enlivex Ltd. Stock? ENLV Key Strengths
- Operating in pharmaceutical sector with potential for high-value therapeutics
- Listed on Nasdaq suggesting some level of institutional oversight
- No disclosed long-term debt burden apparent
- Balance sheet expanded materially in 2025, with total assets of about $2.33 billion and shareholders' equity of about $1.93 billion
- Operating cash burn improved year over year, with net cash used in operations declining to about $10.4 million from $13.0 million
- R&D spending fell to about $9.2 million in 2025 from $10.6 million in 2024, extending projected runway through approximately the end of 2027
ENLV Stock Risks: Enlivex Ltd. Investment Risks
- Complete absence of revenue and profitability data indicates pre-commercial or severely underperforming operations
- No visibility into cash position, liquidity, or burn rate creates inability to assess financial stability
- Zero insider purchases in last 90 days suggests lack of management confidence
- Only 1 metric available indicates incomplete or missing financial disclosures
- Pharmaceutical sector inherently high-risk with unproven product pipeline
- No product revenue and continuing operating losses mean the underlying biotech business remains unproven
- 2025 earnings quality is weak because profit was driven by unrealized fair-value gains on digital assets and a purchase option, not recurring operations
- Balance sheet concentration and financing risk are high, with about 99.5% of assets tied to RAIN-related holdings and a March 2026 senior secured convertible note adding collateral, repayment, and dilution risk
Key Metrics to Watch
- Revenue generation and path to profitability
- Cash position and runway for operations
- Clinical trial progress and regulatory milestones
- Insider trading activity indicating management confidence
- Quarterly operating cash burn relative to management's runway assumptions
- Clinical trial progress for Allocetra alongside the share of total assets and equity concentrated in RAIN-related holdings
Enlivex Ltd. (ENLV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ENLV Profit Margin, ROE & Profitability Analysis
ENLV vs Healthcare Sector: How Enlivex Ltd. Compares
How Enlivex Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Enlivex Ltd. Stock Overvalued? ENLV Valuation Analysis 2026
Based on fundamental analysis, Enlivex Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Enlivex Ltd. Balance Sheet: ENLV Debt, Cash & Liquidity
ENLV Revenue Growth, EPS Growth & YoY Performance
ENLV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Enlivex Ltd. (CIK: 0001596812)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Nov 14, 2024 | SC 13G | armistice-enlv093024.htm | View → |
| Jun 27, 2019 | SC 13G | sc13g0619hbl_enlivexthera.htm | View → |
| Jun 26, 2019 | SC 13G | sc13g0619kretzmer_enlivex.htm | View → |
| Jun 26, 2019 | SC 13G | sc13g0619kip_enlivexthera.htm | View → |
| Jun 19, 2019 | SC 13G | sc13g0619hobi_enlivextherap.htm | View → |
❓ Frequently Asked Questions about ENLV
What is the AI rating for ENLV?
Enlivex Ltd. (ENLV) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 85% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENLV's key strengths?
Claude: Operating in pharmaceutical sector with potential for high-value therapeutics. Listed on Nasdaq suggesting some level of institutional oversight. ChatGPT: Balance sheet expanded materially in 2025, with total assets of about $2.33 billion and shareholders' equity of about $1.93 billion. Operating cash burn improved year over year, with net cash used in operations declining to about $10.4 million from $13.0 million.
What are the risks of investing in ENLV?
Claude: Complete absence of revenue and profitability data indicates pre-commercial or severely underperforming operations. No visibility into cash position, liquidity, or burn rate creates inability to assess financial stability. ChatGPT: No product revenue and continuing operating losses mean the underlying biotech business remains unproven. 2025 earnings quality is weak because profit was driven by unrealized fair-value gains on digital assets and a purchase option, not recurring operations.
What is ENLV's revenue and growth?
Enlivex Ltd. reported revenue of N/A.
Does ENLV pay dividends?
Enlivex Ltd. does not currently pay dividends.
Where can I find ENLV SEC filings?
Official SEC filings for Enlivex Ltd. (CIK: 0001596812) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENLV's EPS?
Enlivex Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ENLV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Enlivex Ltd. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ENLV stock overvalued or undervalued?
Valuation metrics for ENLV: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ENLV stock in 2026?
Our dual AI analysis gives Enlivex Ltd. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENLV's free cash flow?
Enlivex Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does ENLV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).